Close

Arena (ARNA) Short Interest Still High into Q4 Results

Go back to Arena (ARNA) Short Interest Still High into Q4 Results

Arena (ARNA), VIVUS (VVUS) Face Uphill Obesity Battle as Costs Play Key Role

March 21, 2013 6:57 AM EDT

Arena Pharma (Nasdaq: ARNA) and VIVUS (Nasdaq: VVUS) are fighting the good fight. For profits.

Since the two received FDA approval for their respective obesity pills, Belviq and Qsymia, respectively, the drugs have yet to catch on with patients. Qsymia prescriptions are down 22 percent from a top hit on February 8th, which Belviq is yet to go on sale in the... More